Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886660 | 0.85 | TSHR (0.60) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL17886656 | 0.81 | TSHR (0.54) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL18627496 | 0.81 | MEN1 (0.50) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL10324681 | 0.80 | TSHR (0.56) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL3600635 | 0.80 | TSHR (0.48) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL16565388 | 0.80 | TSHR (0.53) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL13543984 | 0.79 | TSHR (0.64) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL3246933 | 0.79 | TSHR (0.57) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL240381 | 0.79 | TSHR (0.57) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL6543780 | 0.78 | TSHR (0.63) | TSHRALOX15ATMOPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104069112-A | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INT | 2014-10-01 | — | — | CN | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | TSHR 1555/4885ALOX15 1596/4885ATM 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.